Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

PHASE 3 STUDY: CANFOSFAMIDE (C, TLK286) PLUS CARBOPLATIN (P) VS LIPOSOMAL DOXORUBICIN (D) AS 2ND LINE THERAPY OF PLATINUM (PL) RESISTANT OVARIAN CANCER (OC)

PHASE 3 STUDY: CANFOSFAMIDE (C, TLK286) PLUS CARBOPLATIN (P) VS LIPOSOMAL DOXORUBICIN (D) AS 2ND LINE THERAPY OF PLATINUM (PL) RESISTANT OVARIAN CANCER (OC) . International Journal of Gynecologic Oncology. 2007.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.